Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Grassley speaks on wheelchairs

This article was originally published in The Gray Sheet

Executive Summary

Senate Finance Committee Chairman Chuck Grassley called newly proposed Medicare wheelchair rules "overly restrictive, confusing and impossible to successfully implement in the proposed time frame," in a Sept. 29 letter to CMS, echoing opinions of power mobility device providers. CMS' interim final rule on power mobility devices is scheduled to go into effect Oct. 25, 2005 (1"The Gray Sheet," Sept. 19, 2005, p. 9)...

You may also be interested in...



Power Wheelchair Suppliers Spar With CMS Over New Regs

Suppliers of power mobility equipment say CMS' new interim final rule on the devices creates a system that is more complicated than the one it replaces and should not be implemented until next April

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

With One Launch Under Way, SpringWorks Ramps Up For A Second

The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel